Glasgow, United Kingdom
MGB Biopharma Limited is a UK-based biotechnology startup with a focus on developing a new class of anti-infective medicine. Their antibiotics, based on Minor Groove Binder (MGBs) compounds, present a promising solution to the rising issue of antibiotic resistance. The company's experienced management team is dedicated to developing small molecules with specific antibacterial activity against susceptible and resistant bacteria, a truly novel mechanism of action not seen in a new class of drug since 2000.
The startup's lead drug candidate, MGB-BP-3, is currently in Phase I clinical safety studies and is expected to complete by the end of 2015. This marks significant progress since the company's inception in 2009. MGB Biopharma has received funding from a syndicate of Scottish Enterprise, TRICAPITAL, Barwell Plc, and Archangels, some of Scotland's leading business angels, in collaboration with Scottish Enterprise.
With its innovative approach to tackling bacterial infections, MGB Biopharma is poised to make a valuable contribution to the biotechnology and healthcare industries, addressing a critical need for new and effective anti-infectives.
